Bicara Therapeutics (NASDAQ:BCAX) Price Target Raised to $16.00

Bicara Therapeutics (NASDAQ:BCAX) had its price target lifted by The Goldman Sachs Group from $14.00 to $16.00 in a research note published on Tuesday,Benzinga reports. The Goldman Sachs Group currently has a neutral rating on the stock.

Several other research firms have also recently weighed in on BCAX. Citigroup started coverage on shares of Bicara Therapeutics in a research report on Thursday, January 29th. They issued an “outperform” rating on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Friday, January 9th. Bank of America started coverage on shares of Bicara Therapeutics in a research note on Wednesday, March 25th. They issued a “buy” rating and a $35.00 price target for the company. Wedbush reissued an “outperform” rating and issued a $30.00 price target on shares of Bicara Therapeutics in a report on Tuesday. Finally, HC Wainwright raised their price objective on shares of Bicara Therapeutics from $40.00 to $42.00 and gave the company a “buy” rating in a research report on Tuesday. Eight investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $28.00.

Bicara Therapeutics Stock Performance

NASDAQ:BCAX opened at $21.47 on Tuesday. Bicara Therapeutics has a 52-week low of $7.80 and a 52-week high of $21.50. The stock has a fifty day moving average of $17.36 and a 200 day moving average of $16.73. The firm has a market capitalization of $1.41 billion, a price-to-earnings ratio of -8.49 and a beta of -1.23.

Bicara Therapeutics (NASDAQ:BCAX) last announced its earnings results on Monday, March 30th. The company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.04. Equities analysts forecast that Bicara Therapeutics will post -2.59 earnings per share for the current fiscal year.

Insider Buying and Selling at Bicara Therapeutics

In other Bicara Therapeutics news, COO Ryan Cohlhepp sold 12,500 shares of the business’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $19.66, for a total value of $245,750.00. Following the completion of the sale, the chief operating officer directly owned 200,641 shares of the company’s stock, valued at $3,944,602.06. The trade was a 5.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Ivan Hyep sold 9,200 shares of the company’s stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $18.52, for a total transaction of $170,384.00. Following the sale, the chief financial officer owned 145,355 shares of the company’s stock, valued at approximately $2,691,974.60. The trade was a 5.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 137,969 shares of company stock worth $2,586,198 over the last 90 days. Company insiders own 15.50% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Bicara Therapeutics in the 4th quarter valued at about $45,000. Legal & General Group Plc boosted its holdings in Bicara Therapeutics by 64.1% during the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after acquiring an additional 1,233 shares during the period. Ameritas Investment Partners Inc. grew its position in Bicara Therapeutics by 73.0% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock worth $32,000 after acquiring an additional 1,474 shares during the last quarter. Larson Financial Group LLC increased its stake in Bicara Therapeutics by 1,015.5% in the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock worth $62,000 after purchasing an additional 3,595 shares during the period. Finally, Tower Research Capital LLC TRC increased its stake in Bicara Therapeutics by 419.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock worth $44,000 after purchasing an additional 3,866 shares during the period.

Bicara Therapeutics News Roundup

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its 2026 quarterly and full‑year EPS forecasts (Q1–Q4 and FY2026) and reiterated a “Buy” rating with a $42 price target — the firm trimmed expected losses for each quarter and the year, signaling improved analyst confidence. Read More.
• Positive Sentiment: Wedbush reaffirmed an “Outperform” rating on BCAX, adding third‑party validation from another biopharma‑focused shop that can boost investor sentiment. Read More.
• Positive Sentiment: Goldman Sachs published bullish commentary indicating expected upside for BCAX, which helps drive demand from institutional and retail investors watching analyst cues. Read More.
• Positive Sentiment: Wells Fargo highlighted strong price‑appreciation potential for Bicara, contributing additional buy‑side momentum. Read More.
• Positive Sentiment: Aggregate Wall Street price targets (per Zacks) imply roughly ~55% upside from current levels — the headline can attract momentum traders and investors seeking high‑growth biotechs. Read More.
• Neutral Sentiment: Recent Q4 2025 results showed a slight beat to loss estimates (EPS better than consensus by $0.04), but the company remains unprofitable with consensus FY2026 EPS still a negative figure — investors are reacting to rate of improvement, not profitability yet. Read More.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.